

Pneumeric is a **Medical Device** company improving care in trauma for those affected by pneumothorax



Problem



Pneumothorax is a fatal clinical condition wherein the lungs collapse and air leaks into the space between the lung and chest wall


It needs immediate treatment, but the current treatment of needle decompression has a failure rate of 20-50%

Solution



The Pneumeric Capnospot™, a patented, rapid, lightweight, portable solution visually detects needle placement using Colorimetric Capnography utilizing a “Litmus paper” type outcome to detect the presence of CO₂

Market Opportunity



Competitive Analysis

	Cost	Easily Portable	Level of Difficulty	Setup Time	Binary Conf.	False Positive
Capnospot™	\$20	Yes	Easy	Minimal	Yes	No
Spring-Loaded Angiocatheters	\$35	Yes	Advanced	Minimal	Yes	Yes
Ultrasound	>\$1,500	No	Advanced	Extensive	No	No
Water Seal Chamber	\$500	No	Advanced	Extensive	No	No

Business Model

B2B2C utilizing a wholesale distributor and retail direct-to-user model.

Marketing Strategy

Civilian Market

Marketing

Clarion

Distributors

Military Market



Founder Team



John Aho MD, Ph.D.

Founder, CEO, & Chief Medical Officer



Sasha Gentling, CFA

Co-founder & Executive Vice President



Jonathan Sackner-Bernstein, MD

Chief Regulatory Officer



Todd Wiltshire

Chief Financial Officer

Ask & Usage

Pneumeric seeks \$1M in preferred equity Series A funding:

- Clinical Studies
- Marketing
- Business Development
- IT & Regulatory
- General & Administrative

